EUVIMEDEUVIMED entdecken
Crossref

Engineering a Translational Human Thrombus Platform to Evaluate Clinical Therapies in Ischemic Stroke

Charly Helaine iD, Audrey Picot iD, Mialitiana Solo Nomenjanahary iD, Mélina Ianszen, Didier Goux iD, Christophe Gaudin, Jerome Parcq iD, Richard Macrez iD, Benoit Ho-Tin-Noé iD, Denis Vivien iD, Audrey M Thiebaut iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 29.10.2026

DOI: 10.1161/atvbaha.126.325244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, online erschienen am 29.10.2026. Verfasst von Charly Helaine und 10 weiteren Autor:innen. Beteiligte Einrichtung: Normandie Université, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institut Blood and Bra…. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recanalization failure after ischemic stroke remains a major clinical challenge, partly because cerebral thrombi display marked spatial heterogeneity that is poorly reproduced by experimental models. Here, we engineered a translational human blood–based thrombus platform that recapitulates key histological features of patient-derived stroke clots. METHODS: Under controlled conditions, the platform generated reproducible thrombi with pronounced interthrombus and intrathrombus heterogeneity, including alternating red blood cell–rich and platelet-rich territories. Multiscale structural and biochemical analyses confirmed the successful replication of the clinical biphasic organization associated with resistance to rtPA (recombinant tissue-type plasminogen activator): a compact outer fibrin shell containing focal accumulations of plasminogen activator inhibitor-1, and a dense inner core further stabilized by neutrophil extracellular traps. RESULTS: Functional thrombolysis assays demonstrated that this architecture directly dictates lytic susceptibility. Specifically, artificially breaching the outer fibrin shell (halved thrombi) significantly accelerated early rtPA-mediated lysis, proving its role as an effective physical barrier. Furthermore, lytic response was inherently linked to clot composition: platelet-rich thrombi with dense plasminogen activator inhibitor-1 and neutrophil extracellular trap networks exhibited profound resistance to standard rtPA compared with red blood cell–rich clots. Supporting the platform’s translational relevance, this structural resistance was successfully overcome by clinically relevant strategies, including tenecteplase and adjunctive DNAse, consistent with observations from human stroke cohorts. CONCLUSIONS: By accurately reproducing the spatial organization and differential thrombolytic responses of human cerebral thrombi, this translational framework provides a robust preclinical tool to dissect lytic resistance and evaluate next-generation precision reperfusion therapies. Furthermore, developing robust ex vivo human platforms is increasingly critical to align with the replacement, reduction, refinement ethical guidelines for animal research.

Schlagwörter

Stichwörter der Autor:innen

ischemic strokeperoxidasestroketenecteplasethrombosis

Autor:innen und Institutionen

  • Normandie Université, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institut Blood and Brain @ Caen-Normandie (BB@C), France (C.H., A.P., R.M., D.V., A.M.T.).
  • Faculté de Pharmacie de Paris, Université Paris Cité, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie, France (M.S.N., B.H.-T.-N.).
  • Op2Lysis SAS, Boulogne-Billancourt, France (M.I., C.G., J.P., A.M.T.).
  • Légia Park Liège, Belgium (M.I., C.G., J.P., A.M.T.).
  • Normandie Université, UNICAEN, Université Caen Normandie, US EMerode, CMAbio3: Centre de Microscopie Appliquée à la Biologie, France (D.G.).
  • Emergency Departement (R.M.), CHU Caen CHU de Caen Côte de Nacre, France.

ORCID-Profile: Charly Helaine, Audrey Picot, Mialitiana Solo Nomenjanahary, Didier Goux, Jerome Parcq, Richard Macrez, Benoit Ho-Tin-Noé, Denis Vivien, Audrey M Thiebaut

Zitieren

APA

Helaine, C., Picot, A., Solo Nomenjanahary, M., Ianszen, M., Goux, D., Gaudin, C., Parcq, J., Macrez, R., Ho-Tin-Noé, B., Vivien, D., & Thiebaut, A. M. (2026). Engineering a Translational Human Thrombus Platform to Evaluate Clinical Therapies in Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.325244

Vancouver

Helaine C, Picot A, Solo Nomenjanahary M, Ianszen M, Goux D, Gaudin C, et al. Engineering a Translational Human Thrombus Platform to Evaluate Clinical Therapies in Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.325244

BibTeX
@article{Helaine2026,
  author = {Helaine, Charly and Picot, Audrey and Solo Nomenjanahary, Mialitiana and Ianszen, Mélina and Goux, Didier and Gaudin, Christophe and Parcq, Jerome and Macrez, Richard and Ho-Tin-Noé, Benoit and Vivien, Denis and Thiebaut, Audrey M},
  title = {Engineering a Translational Human Thrombus Platform to Evaluate Clinical Therapies in Ischemic Stroke},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  doi = {10.1161/atvbaha.126.325244}
}
Kostenlos starten →